Pyridoxamine, a versatile inhibitor of advanced glycation and lipoxidation reactions

International Congress Series

Volumn 1245, Issue C, 2002, Pages 31-35

  Baynes, John W ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation end product (AGE); Advanced lipoxidation end product (ALE); Diabetes; Dyslipidemia; Pyridoxamine

Indexed keywords

EID: 84894884865     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(02)00880-4     Document Type: Article

References (7)

1. Baynes, J.W., Thorpe, S.R., Glycation and advanced glycation reactions. Turtle, J.R., Kaneko, T., Osato, S., (eds.) Diabetes in the New Millennium, 2000, International Diabetes Federation, Sydney, 337–350.
2. Baynes, J.W., Thorpe, S.R., Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28 (2000), 1708–1716.
3. Khalifah, R.G., Baynes, J.W., Hudson, B.G., Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. 257 (1999), 251–258.
4. Onorato, J.M., Jenkins, A.J., Thorpe, S.R., Baynes, J.W., Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J. Biol. Chem. 275 (2000), 21177–21184.
5. Degenhardt, T.P., Alderson, N.L., Arrington, D.D., Beattie, R.J., Basgen, J.M., Steffes, M.W., Thorpe, S.R., Baynes, J.W., Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61 (2002), 939–950.
6. Baynes, J.W., Alderson, N.L., Chachich, M.E., Youssef, N.N., Jimenez, S.M., Beattie, R.J., Januszewski, A.S., Thorpe, S.R., Pyridoxamine inhibits formation of advanced glycoxidation and lipoxidation end-products and retards development of nephropathy in hyperlipidemic and diabetic rats. Diabetologia, 44(S1), 2001, A33.
7. Stitt, A.W., Gardiner, T.A., Duffy, N., Lichanska, A.M., Boyle, C., Simpson, D.A.C., Alderson, N.L., Januszewski, A.S., Baynes, J.W., Thorpe, S.R., Inhibition of advanced glycation/lipoxidation endproducts (AGE/ALEs) prevents retinopathy in experimental diabetes. Diabetologia, 44(S1), 2001, A290.